Is Nivolumab PD1 or PDL1?

Nivolumab (Nivolumab) is a PD-1 antibody, not a PD-L1 antibody. PD-1 (programmed death-1) is a receptor protein in the immune system that regulates the activity of immune cells by binding to its ligand PD-L1 (programmed death ligand-1). Nivolumab, as a PD-1 antibody, can block the combination of PD-1 and PD-L1, thereby activating the patient's own immune system and enhancing its ability to attack tumor cells. This drug has been widely used in the treatment of various malignant tumors and has achieved certain results.

Nivolumab is a humanizedIgG4 anti-PD-1 monoclonal antibody, which has high affinity for PD-1 and blocks the binding of PD-1 to its ligand PD-L1. In December 2014, the U.S. Food and Drug Administration (FDA) accelerated approval of nivolumab for the treatment of unresectable or metastatic melanoma, and subsequently approved it for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). In addition to melanoma and non-small cell lung cancer, nivolumab has also been shown to be effective against many other malignancies, including Hodgkin lymphoma, hepatocellular carcinoma, and others.

The generic drug Nivolumab is currently on the market in China, but it has not yet been included in medical insurance. This drug is a strictly controlled drug, and its purchase channels are restricted. Specifications The price of each box of 40mg/4ml may be around RMB 4,000. The Turkish version of the nivolumab generic drug listed overseas may cost more than RMB 2,000 per box of 40mg/4ml (the price may fluctuate due to exchange rates). Currently, there is no generic version of nivolumab available on the market. For more drug information and specific prices, please consult a medical consultant.